A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma

Project: Research project

Project Details

Description

A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma
StatusActive
Effective start/end date8/14/198/30/24

Funding

  • Takeda Cambridge Ltd.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.